Want to see GB:ELIX full AI Analyst Report?
Top Page
Elixirr International Plc
(LSE:ELIX)
Select Model
Select Model
Rating:71Outperform
Price Target:
716.00 p
▲(14.01% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by strong underlying fundamentals (growth and profitability), though tempered by rising leverage and weaker operating cash support in 2025. Technical indicators are a notable drag due to a broader downtrend and negative momentum, while reasonable valuation and a solid dividend yield provide partial offset.
Positive Factors
Multi-year revenue scaling
Sustained, large revenue expansion over several years builds a deeper client base and program pipeline, enabling economies of scale in consulting delivery. A larger revenue base supports diversified client exposure, investment in specialist offerings, and a stronger platform to win bigger multi-year engagements.
Negative Factors
Step-up in debt
A sharp increase in absolute debt materially changes the historically low-leverage profile and reduces financial flexibility. Higher interest and principal obligations constrain capacity to fund opportunistic investments or absorb working-capital swings, raising refinancing and covenant risk over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue scaling
Sustained, large revenue expansion over several years builds a deeper client base and program pipeline, enabling economies of scale in consulting delivery. A larger revenue base supports diversified client exposure, investment in specialist offerings, and a stronger platform to win bigger multi-year engagements.
Read all positive factors
Elixirr International Plc (ELIX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£304.01M
Dividend Yield3.8%
Average Volume (3M)102.07K
Price to Earnings (P/E)14.5
Beta (1Y)1.05
Revenue Growth34.36%
EPS Growth18.76%
CountryUK
Employees730
SectorIndustrials
Sector Strength72
IndustryConsulting Services
Share Statistics
EPS (TTM)0.41
Shares Outstanding50,853,348
10 Day Avg. Volume90,889
30 Day Avg. Volume102,073
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)2.76
Price to Sales (P/S)2.63
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,275.00Price Target Upside103.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)£184.67M
Elixirr International Plc Business Overview & Revenue Model
Company Description
Elixirr International plc, along with its various subsidiaries, delivers expert management consulting services across the United Kingdom, the United States, and other international territories. The company's core offerings encompass creative strat...
How the Company Makes Money
Elixirr primarily makes money by delivering professional services to clients under consulting engagements. Revenue is generated from fees billed for advisory and delivery work (typically based on time-and-materials day rates or fixed-fee project s...
Elixirr International Plc Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
76
Positive
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 149.60M | 111.34M | 85.89M | 71.75M | 50.61M |
| Gross Profit | 44.80M | 35.81M | 29.26M | 23.16M | 17.70M |
| EBITDA | 39.55M | 27.96M | 25.78M | 20.02M | 14.46M |
| Net Income | 19.70M | 16.38M | 17.24M | 12.87M | 10.14M |
Balance Sheet | |||||
| Total Assets | 251.08M | 175.89M | 154.40M | 128.66M | 107.17M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 7.53M | 18.13M | 20.43M | 31.80M |
| Total Debt | 33.52M | 4.90M | 5.36M | 5.14M | 5.25M |
| Total Liabilities | 108.56M | 43.78M | 34.84M | 32.74M | 21.13M |
| Stockholders Equity | 142.53M | 132.11M | 119.56M | 95.92M | 86.04M |
Cash Flow | |||||
| Free Cash Flow | 31.48M | 28.76M | 16.67M | 15.40M | 14.23M |
| Operating Cash Flow | 31.55M | 28.84M | 16.79M | 15.73M | 14.33M |
| Investing Cash Flow | -36.56M | -21.11M | -14.82M | -18.53M | -3.24M |
| Financing Cash Flow | 2.92M | -18.58M | -4.06M | -8.85M | 3.11M |
Elixirr International Plc Technical Analysis
Negative
628.00
Price Trends
643.05
Negative
671.87
Negative
696.43
Negative
Market Momentum
-12.43
Positive
38.14
Neutral
30.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ELIX, the sentiment is Negative. The current price of 628 is above the 20-day moving average (MA) of 625.30, below the 50-day MA of 643.05, and below the 200-day MA of 696.43, indicating a bearish trend. The MACD of -12.43 indicates Positive momentum. The RSI at 38.14 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ELIX.
Elixirr International Plc Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £320.65M | 26.04 | 6.46% | 3.42% | 2.11% | 818.58% | |
71 Outperform | £304.01M | 14.49 | 15.00% | 3.80% | 34.36% | 18.76% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £2.44B | 16.41 | 17.55% | 1.84% | 1.20% | 221.80% | |
60 Neutral | £505.41M | 16.04 | 9.94% | 2.12% | 12.82% | 16.40% | |
56 Neutral | £83.74M | 26.44 | 4.61% | 8.92% | 8.23% | 120.59% | |
46 Neutral | £309.63M | -1.51 | -677.10% | 5.94% | -16.13% | -1315.87% |
* Industrials Sector Average
GB:ELIX
Elixirr International Plc
594.00
-126.21
-17.52%
GB:CPI
Capita plc
252.50
7.50
3.06%
GB:GTLY
Gateley (Holdings)
59.50
-61.94
-51.00%
GB:DATA
GlobalData
70.90
-72.02
-50.39%
GB:SRP
Serco Group plc
252.20
35.19
16.22%
GB:YOU
Yougov plc
270.60
-76.45
-22.03%
Elixirr International Plc Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Elixirr Posts Record H1 Results and Bolsters U.S. Push with New Broker
Positive
Aug 3, 2026
Elixirr International, a global challenger consulting firm focused on commercial transformation, technology and AI services, reported strong growth for the first half of 2026, highlighting its expanding role in AI-enabled consulting. The London-li...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Elixirr CFO Exercises Share Options Without Diluting Equity
Positive
Jul 10, 2026
Elixirr International Plc reported that Chief Financial Officer and Company Secretary Nicholas Willott has exercised options over 100,000 ordinary shares at an exercise price of 43.365p per share, with the shares sourced from the company’s E...
Business Operations and StrategyShareholder Meetings
Elixirr Wins Strong Shareholder Backing as All AGM Resolutions Pass
Positive
Jun 30, 2026
Elixirr International plc, the award-winning challenger consultancy, operates globally across diverse sectors and focuses on collaborative, outcome-driven advisory services that differentiate it from larger incumbents. Since its 2009 founding, the...
Business Operations and StrategyDividendsShareholder Meetings
Elixirr Sets AGM Date and Confirms Final Dividend Timetable
Positive
Jun 2, 2026
Elixirr International has published its notice of Annual General Meeting, to be held on 30 June 2026 at the Royal Berkshire Hotel in Ascot, with the AGM materials and 2025 Annual Report made available both via the National Storage Mechanism and on...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Elixirr issues new shares to settle TRC acquisition earn-out
Positive
May 20, 2026
Elixirr International has issued 822,194 new ordinary shares to satisfy the equity component of contingent consideration tied to the 2025 performance of its acquired U.S. advisory firm TRC Advisory, valuing the issuance at £5.9 million. The n...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.